Related Experiment Video

Updated: Apr 1, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K

Circulating thrombospondine-2 in patients with moderate-to-severe chronic heart failure due to coronary artery

Alexander E Berezin1, Alexander A Kremzer2, Tatayna A Samura2

  • 1Department of Internal Medicine; Department of Clinical Pharmacology, State Medical University, Zaporozhye 69035, Ukraine. dr_berezin@mail.ru.

Journal of Biomedical Research
|October 2, 2015
PubMed

Insights

Elevated circulating thrombospondin-2 (TSP-2) predicts worse outcomes in patients with chronic heart failure (CHF) from coronary artery disease (CAD). Higher TSP-2 levels are linked to increased mortality and rehospitalization risk in CHF patients.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Chronic heart failure (CHF) is a major cause of illness and death.
  • Ischemic CHF due to coronary artery disease (CAD) presents significant clinical challenges.
  • Identifying reliable prognostic markers for CHF is crucial for patient management.

Purpose of the Study:

  • To assess the predictive capability of circulating thrombospondin-2 (TSP-2) for survival in patients with ischemic CHF.
  • To determine the association between TSP-2 levels and mortality and rehospitalization in CAD patients with CHF.

Main Methods:

  • Prospective study evaluating circulating TSP-2 levels.
  • Median follow-up of 2.18 years.
  • Statistical analysis to assess TSP-2 as an independent predictor of all-cause mortality, CHF-related death, and rehospitalization.

Main Results:

  • Higher median circulating TSP-2 levels were observed in patients who died compared to survivors (1.03 ng/mL vs. 0.63 ng/mL, P<0.001).
  • Circulating TSP-2 independently predicted all-cause mortality (OR=1.27), CHF-related death (OR=1.16), and CHF-related rehospitalization (OR=1.12).
  • Significant correlations were found between increased TSP-2 and adverse outcomes.

Conclusions:

  • Increased circulating TSP-2 is a significant predictor of adverse outcomes in patients with symptomatic CHF and CAD.
  • Elevated TSP-2 levels are associated with increased 3-year CHF-related death, all-cause mortality, and recurrent hospitalization risk.
  • TSP-2 may serve as a valuable prognostic biomarker in managing ischemic CHF.

Keywords:
chronic heart failurehospitalizationprognosissurvivalthrombospondine-2

More Related Videos

Author Spotlight: Enhancing Coronary Artery Revascularization05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.4K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
580
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
983
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
544